Boston Scientific beats Q1 revenue expectations, except for endoscopy sales

US-based medtech firm Boston Scientific, a competitor of Danish firm Ambu on the endoscopy market, has delivered Q1 results on both top and bottom lines that exceed estimations, though according to these, endoscopy sales have underperformed slightly.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Endoscopy president to leave Boston Scientific
For subscribers